Alluvi, known as BI 4744, represents a notable breakthrough in obesity therapy. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide targets demonstrates impressive efficacy in https://wearethelist.com/story24368056/alluvi-a-comprehensive-dive-into-the-retatrutide-s-possibilities